NDAORALTABLET
Approved
Mar 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ALDOCLOR-250 (chlorothiazide; methyldopa) by Merck & Co. is clinical pharmacology: the mechanism of the antihypertensive effect of thiazides is unknown. Approved for pregnancy, just, heart failure and 2 more indications. First approved in 1968.
Drug data last refreshed 29m ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALDOCLOR-250 is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and methyldopa (a centrally-acting antihypertensive) indicated for hypertension management. Chlorothiazide increases sodium and chloride excretion via the distal renal tubule, while methyldopa reduces peripheral vascular resistance through central sympathetic inhibition. The combination targets multiple pathways to reduce blood pressure in patients requiring dual-agent therapy.
LOE Approaching
Product approaching loss of exclusivity with minimal direct commercial activity; legacy brand teams focus on maintenance rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY: The mechanism of the antihypertensive effect of thiazides is unknown. Chlorothiazide does not usually affect normal blood pressure. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are…
Indications (5)
Worked on ALDOCLOR-250 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.